Tracking circulating tumor DNA could indicate gastroesophageal cancer treatment response

Monitoring levels of DNA shed by tumors and circulating in the bloodstream could help doctors accurately assess how gastroesophageal cancers are responding to treatment, and potentially predict future prognosis, suggests a new study led by researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

Amazon veteran Missy Krasner shares why now is the time for young health startups to go shopping

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) If you want to get a pulse

May 15, 2024

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis | Psychedelic Invest

Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing novel medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies for unmet medical needs, is

January 24, 2024

Biopharma Collaboration: Roadmap Towards the Facility of the Future

Panelists: Janmeet Anant, PhD, PMP, RACSenior Regulatory ConsultantMerck Guido Kremer-van der KampSenior Consultant,Global BioPharm Center of ExcellenceMerck Adam SokolnickiDirector of the MSAT-Downstream group of Biomanufacturing

June 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.